196 related articles for article (PubMed ID: 32967883)
1. Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.
le Guevelou J; Debaigt C; Saada-Bouzid E; Viotti J; Khalladi N; Thibouw D; Penel N; Sunyach MP; Moureau-Zabotto L; Benchalal M; Veresezan O; Ducassou A; le Pechoux C; Jolnerovski M; Bazille C; Vaur D; Escande A; Serre R; Lovera C; Thariat J
BMJ Open; 2020 Sep; 10(9):e038391. PubMed ID: 32967883
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma.
Feng XY; Li J; Li AM; Jing SH; Zhu XX; Wang Z
World J Surg Oncol; 2022 Sep; 20(1):322. PubMed ID: 36171617
[TBL] [Abstract][Full Text] [Related]
3. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase II trial of stereotactic body radiotherapy in combination with
Spindler NJ; Persson GF; Theile S; Nielsen DL; Høgdall EV; Al-Farra G; Hendel HW; Lorentzen T; Svane IM; Lindberg H; Eefsen RL
BMJ Open; 2023 Jan; 13(1):e063500. PubMed ID: 36717150
[TBL] [Abstract][Full Text] [Related]
5. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
Biau J; Thivat E; Millardet C; Saroul N; Pham-Dang N; Molnar I; Pereira B; Durando X; Bourhis J; Lapeyre M
BMC Cancer; 2020 Aug; 20(1):730. PubMed ID: 32758188
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma.
Loi M; Duijm M; Baker S; Rossi L; Grunhagen D; Verhoef C; Nuyttens J
Radiol Med; 2018 Nov; 123(11):871-878. PubMed ID: 29923086
[TBL] [Abstract][Full Text] [Related]
7. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
8. Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer.
Tibdewal A; Agarwal J; Mummudi N; Noronha V; Prabhash K; Patil V; Purandare N; Janu A; Kaushal R; Kannan S
BMJ Open; 2021 Feb; 11(2):e041345. PubMed ID: 33589450
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
10. A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma.
Harris JP; Park J; Ku E; Seyedin S; Stitzlein R; Goldin A; Chen WP; McLaren C; Chen AM; Chow W
Cancer Control; 2024; 31():10732748241237331. PubMed ID: 38449377
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma.
Liu Q; Zhu Z; Chen Y; Deng J; Ai D; Liu Q; Wang S; Wu S; Chen J; Zhao K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):707-715. PubMed ID: 32417405
[TBL] [Abstract][Full Text] [Related]
12. [The role of radiotherapy to the primary tumor and metastases in patients with oligometastatic prostate cancer].
Le Roy T; Baron D; Vandendorpe B; Bataille B; Hannoun-Levi JM; Blanchard P; Lartigau E; Latorzeff I; Pasquier D
Cancer Radiother; 2021 Oct; 25(6-7):526-532. PubMed ID: 34400086
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
[TBL] [Abstract][Full Text] [Related]
14. Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial.
Tibdewal A; Agarwal JP; Srinivasan S; Mummudi N; Noronha V; Prabhash K; Patil V; Purandare N; Janu A; Kannan S
BMJ Open; 2021 Mar; 11(3):e043628. PubMed ID: 33727268
[TBL] [Abstract][Full Text] [Related]
15. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M; Pointreau Y; Sargos P; Meyer E; Schick U; Hasbini A; Rio E; Bera G; Ruffier A; Quivrin M; Chasseray M; Latorzeff I; Martin E; Guimas V; Pommier P; Leroy T; Ronchin P; Lepinoy A; Grand A; Cartier L; Didas O; Denis F; Libois V; Blanc-Lapierre A; Supiot S
Clin Transl Radiat Oncol; 2023 May; 40():100613. PubMed ID: 36968576
[TBL] [Abstract][Full Text] [Related]
19. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
